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Abstract
Background: Head and neck squamous cell carcinomas (HNSCCs) represent a heterogeneous group of cancers
for which human papilloma virus (HPV) infection is an emerging risk factor. Previous studies showed promoter
hypermethylation in HPV(+) oropharyngeal cancers, but only few consistent target genes have been so far
described, and the evidence of a functional impact on gene expression is still limited.
Methods: We performed global and stratified pooled analyses of epigenome-wide data in HNSCCs based on the
Illumina HumanMethylation450 bead-array data in order to identify tissue-specific components and common viral
epigenetic targets in HPV-associated tumours.
Results: We identified novel differentially methylated CpGs and regions associated with viral infection that are
independent of the anatomic site. In particular, most hypomethylated regions were characterized by a marked loss
of CpG island boundaries, which showed significant correlations with expression of neighbouring genes. Moreover,
a subset of only five CpGs in a few hypomethylated regions predicted HPV status with a high level of specificity in
different cohorts. Finally, this signature was a better predictor of survival compared with HPV status determined by
viral gene expression by RNA sequencing in The Cancer Genome Atlas cohort.
Conclusions: We identified a novel epigenetic signature of HPV infection in HNSCCs which is independent of the
anatomic site, is functionally correlated with gene expression and may be leveraged for improved stratification of
prognosis in HNSCCs.




Athena Sklias and Davide Degli Esposti are equal contributor for first
authorship.
Davide Degli Esposti, Zdenko Herceg and Ellen Van Obberghen-Schilling
contributed equal senior authorship.
†Equal contributors
1Epigenetics Group, International Agency for Research on Cancer (IARC), 150
Cours Albert Thomas, 69008 Lyon, France
3Université Côte d’Azur, CNRS, Inserm, Institut de Biologie Valrose (iBV), 06100
Nice, France
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Degli Esposti et al. Genome Medicine  (2017) 9:33 
DOI 10.1186/s13073-017-0419-z
Background
Human papilloma virus (HPV)(+)-associated head and
neck squamous cell carcinomas (HNSCCs) have been
recently shown to present characteristic mutations in
various cancer-associated genes, including mutations
and focal amplifications of the oncogene PIK3CA and
cell cycle gene E2F1, and truncating mutations in TRAF3
[1]. Recently, several studies have used gene-specific and
genome-wide approaches to examine epigenetic changes
such as DNA methylation in HNSCCs [1–9]. These
studies identified hypermethylated CpGs in the promoter
of a few genes associated with HPV(+) status. However,
the intrinsic heterogeneity of the disease and the relatively
limited sample size of individual studies tend to limit the
power of identifying the impact of HPV on DNA methyla-
tion in HNSCCs. To address these limitations and to
identify common HPV epigenetic targets in HNSCCs
across different anatomical sites with greater power, we
performed a pooled analysis of epigenome-wide data in
HNSCCs based on the Illumina HumanMethylation450
bead-array data. Finally, we tested whether a unique HPV-
induced DNA methylation signature might be found in
HNSCCs and might be of clinical relevance in addition to
other current diagnostic and prognostic markers, such as




Thirty-eight HNSCCs from a French cohort (FITMA-
NET, CAL/CHU Tumour bank) included 9 HPV(+) and
29 HPV(–) fresh frozen biopsies. For this cohort,
Illumina Infinium HumanMethylation 450 K (HM450K)
was performed on a subset of 6 HPV(+) and 6 HPV(–)
cases. The remaining cases were used for the validation
of the predictive signature by pyrosequencing.
The second cohort comprised 278 HNSCC cases from
The Cancer Genome Atlas (TCGA) cohort, 36 HPV(+)
and 243 HPV(–) [1]. We excluded one HPV(–) case
from the original dataset since it was the only tumour
localized in the lip. For each case, HM450K data were
available and retrieved from the TCGA portal as
described in the following sections. The third cohort
consisted of 48 oropharyngeal SSCs, 24 HPV(+) and 24
HPV(–) from a study conducted at University College
London (UCL) Cancer Institute [2]. Forty-two cases were
microdissected from formalin-fixed paraffin-embedded
(FFPE) tissues, and 6 were fresh frozen biopsies. Figure 1
shows the overall design of the study.
For the FITMANET and TCGA cohorts, anatomic
locations of the tumours were detailed. In particular, 10
anatomic locations were considered. For the UCL
cohort, all cases came from the oropharynx, and details
Fig. 1 Flow chart illustrating the overall design of the study
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on sublocalization were not available. Thus, they were
all considered as originating from the oropharynx. In
our analysis, we grouped the 10 organs into three dis-
tinct anatomic sites, namely oral cavity (alveolar ridge,
buccal mucosa, floor of mouth, hard palate oral cavity,
oral tongue), oropharynx (base of the tongue, tonsils,
oropharynx) and neck (hypopharynx and larynx).
Determination of HPV status
In the FITMANET cohort, the HPV status was deter-
mined by NucliSENS EasyQ HPV, an mRNA-based assay
which directly detects active HPV oncogenes (E6/E7
mRNA) in tumour RNA. In the TCGA cohort, HPV
status was defined by an empiric definition of more than
1000 mapped RNA-sequencing reads to viral genes E6
and E7 [1]. In the UCL cohort, HPV status was deter-
mined by CDKN2A (p16) immunostaining and con-
comitant E6 qPCR on the DNA extracted from each
sample [2].
Pooled analysis of DNA methylome data
The raw data (.idat files) were downloaded from the
TCGA cohort and the UCL cohort. The idat files of the
FITMANET cohort were generated by us. All idat files
were obtained using the HM450K BeadChip assay,
which interrogates more than 480,000 CpG sites. We
collected all the idat files from the three cohorts for a
total of 338 cases, of which 66 were HPV(+). Then we
pooled, preprocessed and normalized the data using the
R packages minfi (prefiltering, quality control and
normalization using the funnorm function) [10, 11]
(Fig. 1). Inferred beta values were used to predict gender
as a first quality-control step using the minfi function
getSex. All samples were correctly predicted. A prefilter-
ing step was performed in order to keep only samples
which were technically successful. We excluded 12 sam-
ples (3 HPV(+) and 9 HPV(–)) for which unmethylated
and methylated median log2 intensities were less than
10.5 (default parameters). Among the excluded samples,
11 cases were from the UCL cohort, whereas one case
was from the FITMANET cohort.
A principal component analysis (PCA) was used to
determine whether technical aspects of our pooled
design (cohort, batch ID, tissue conservation microarray
slide or position) might influence variation within the
dataset (Additional file 1). As expected, many technical
aspects accounted for a significant portion of the vari-
ation in the first two principal components, in particular,
sentrix ID, cohort, tissue conservation and batch ID. To
correct this, we used surrogate variable analysis (sva
package) [12], including HPV status, anatomic site and
gender in the full model and anatomic site and gender
in the null model, and we verified the effect of sva on
our data, again using PCA (Additional file 1). For the
stratified analysis, we proceeded similarly, but omitted
the adjustment for anatomic site. Most of the technical
variability was actually corrected, with HPV status be-
coming the most significant in the first principal compo-
nent (Additional file 1).
Multidimensional scaling (MDS) plots were generated
using the mdsPlot function of the R package minfi. MDS
plots were used as an exploratory analysis in order to as-
sess whether distances between samples were associated
with specific covariates (HPV status, smoking status,
alcohol consumption, organ site). Missing data, in
particular for smoking and alcohol consumption, were
excluded from the analysis.
DNA methylome measurement
DNA from the FITMANET cohort was extracted using
the QIAamp DNA mini kit (Qiagen) and quantified with
Nanodrop (Thermo Scientific). Bisulfite conversion and
DNA methylome profiling were carried out as previously
described [13, 14].
Identification of differentially methylated positions
(DMPs) and differentially methylated regions (DMRs)
Identification of DMPs was performed as described
previously [15, 16]. HPV status associated CpGs were se-
lected based on an adjusted p value (false discovery rate,
FDR) less than 0.05 and using a differential methylation
threshold of 20%. While this threshold may lead to an
underestimation of HPV-related methylation changes,
we estimated this to be a better conservative approach
that may avoid the identification of (or reduce the likeli-
hood of identifying) false positive hits due to undetect-
able and/or not adjustable batch effects by the surrogate
variable analysis applied in the study. Identification of
DMRs was performed using the DMRcate R package
[17]. Statistically significant DMRs (FDR <0.05) with at
least three consecutive CpGs included in a bookend of
1000 nucleotides were retained for further analysis.
Transcription factor motif enrichment
We analysed the top 500 hypomethylated and hyper-
methylated regions to identify potential enrichment of
any transcription factor motifs in these regions, using
HOMER [18].
Co-methylation plots
Co-methylation analysis and relative plots were gener-
ated using coMET, an R package and online tool for
visualization of epigenome-wide association study
(EWAS) results in a genomic region of interest [19].
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DNA methylation-gene expression correlation analysis
We performed a correlation analysis between DNA
methylation and the closest gene expression changes for
the DMRs with Δβmax >20% for the TCGA cohort. The
gene expression data (expressed in RSEM) were re-
trieved using the data available in the cBioPortal for
Cancer Genomics (www.cbioportal.org) for each gene. In
order to calculate the fold change between HPV(+) and
HPV(–) cases, we calculated the average expression
levels per HPV status for each gene. We used a starburst
plot to show all the genes presenting DMRs with
Δβmax >20%, using a similar approach as described in
Noushmehr et al. (2010) [20].
Extraction of HPV predictive signatures
Normalized M values were analysed with two class
prediction algorithms. We used the prediction analysis
of microarrays (PAM) algorithm [21] and a random
forest (RF) algorithm [22] to evaluate whether CpG
methylations were associated with HPV status. For each
algorithm, we used HPV status (positive or negative) as
the class for prediction. We randomly split the pooled
datasets into a training and a test set before running the
analysis (training:test set ratio 1:1). We performed five
cross-validations with five distinct training sets and
testing sets randomly selected from all the cases. The
predictive performance of both algorithms was assessed
by the area under the receiver operating characteristic
(ROC) curve (AUC). We used the average methylation
levels of the most recurrent five CpGs across the five
cross-validations to create an average methylation index
(AMI), and we set a β-value cut-off of 0.75 (correspond-
ing to 75% of methylation in the pyrosequencing re-
sults): samples with AMI lower than 0.75 were classified
as HPV(+).
Pyrosequencing analysis
Bisulfite-treated DNA was amplified using primers
targeting CpGs in the B3GALT6-SDF4 locus (cg13924635,
cg22220310, cg14477263), HLTF-HLTF-AS1 locus (cg0727
5648) and SYCP2-FAM127B locus (cg21950459), identified
by the two class predictors. DNA methylation levels at
single CpG sites were determined by pyrosequencing using
PyroMark Q96 ID (Qiagen).
Survival analysis
We performed a Kaplan-Meier survival analysis in the
TCGA cohort using the survival data reported in
Lawrence et al. [1]. We included all the patients for
which days to death or days to last follow-up were
available, thus including 277 patients. We used either
the AMI we built on the five-CpG signature or the HPV
status as determined by viral gene expression using
RNA-sequencing data. Data were analysed using the R
package survival.
Results
HPV(+) HNSSCs show a tissue-independent DNA methylation
signature across anatomic sites
To address the impact of HPV infection on the DNA
methylome in HNSCC with greater power, we collated
two major studies with raw DNA methylome data [1, 2]
and performed additional methylome analyses of 6
HPV(+) and 6 HPV(–) HNSCC samples from a smaller
independent French cohort (FITMANET). Thus, in the
analysis we included the methylome data from different
geographical regions with a total of 338 cases, among
which 66 were HPV(+) (Table 1, Fig. 1). After applying
stringent quality-control filters (see Methods section),
we analysed the methylome of 326 cases, of which 63
Table 1 Patient characteristics of the head and neck cancers for
which DNA methylome data were analysed




Pooled cases 66 (100) 272 (100)
TCGA 36 (54.5) 242 (89.0)
UCL 24 (21 FFPE) (36.4) 24 (21 FFPE (8.8)
FITMANET 6 (9.1) 6 (2.2)
Male 55 (83.3) 195 (71.7)
Female 11 (17.7) 77 (28.3)
Median age (range) 59 (35–86) 62 (19–90)
Tobacco smoking
Never/light smokers 17 (25.7) 54 (19.8)
Smokers 25 (37.9) 218 (80.0)
Not available 24 (36.4) 25 (9.2)
Alcohol consumption
No 9 (13.6) 83 (30.5)
Yes 32 (48.5) 159 (58.5)
Not available 25 (37.9) 30 (11.0)
Tumour stage
T1 8 (12.1) 13 (4.8)
T2 19 (28.8) 49 (18.0)
T3 9 (13.6) 64 (23.5)
T4 (A + B) 28 (42.4) 118 (43.4)
Not available 2 (3.1) 28 (10.3)
Tumour site
Oral cavity 12 (18.2)b 162 (59.5)
Oropharynx 51 (77.3)c 35 (12.9)
Neck (hypopharynx and larynx) 3 (4.5)d 75 (27.6)
aPercentage calculated using the total number of cases in the group of reference
bHPV16: 8 cases, HPV33: 4 cases
cHPV16: 48 cases, HPV33: 3 cases (1 co-infection with HPV16), HPV35: 1 case
dHPV16: 3 cases (2 cases in hypopharynx, 1 case in larynx)
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were HPV(+). An initial multidimensional scaling (MDS)
analysis, using normalized logit-transformed methylation
values for the most variable probes (4500 probes) to
calculate their Euclidean distance, showed that cancer
samples from the three datasets clustered clearly in two
separate groups based on their HPV status (Fig. 2a,
Additional file 2: Figure S1A–C). Importantly, these
clusters did not associate with anatomic site, smoking
habits and alcohol consumption (Fig. 2b–d).
We identified differentially methylated positions (DMPs,
FDR <0.05 and differential methylation, Δβ >20%) in the
whole dataset, after gender and anatomic site adjustment
(see Methods section). Unsupervised clustering showed
that 2410 DMPs (1023 hypermethylated CpGs, mapping
to 510 genes; 1387 hypomethylated CpGs, mapping to 756
genes, for a total of 1266 genes) comprised one distinct
cluster that includes the majority of HPV(+) cases (53/63,
84%) (Fig. 2e). To rule out that these differences are due
to the different HPV prevalence in the different organ
sites (59%, 7% or 4% in oropharynx, oral cavity and
hypopharynx-larynx, respectively), we tested whether the
2410 DMPs found in the whole datasets were able to
correctly identify HPV(+) cases in the different organ sites.
As shown in Additional file 2: Figure S2A–C, most
HPV(+) cases (53/63) clustered together in the different
organ sites, indicating that these DMPs are associated to
the HPV status independently of the anatomic site.
Then, we stratified the tumours for anatomic site
(adjusting for gender) and found organ-specific pat-
terns of differential methylation associated with HPV
status, without evident cohort effects (Additional file 2:
Figure S1D–F). However, in this case the different
prevalence of HPV in the different organ groups and
the low number of cases may hamper the significance
of an HPV signature specific for each different tissue or
organ group. Thus, the tissue-specific epigenetic im-
pact of the virus remains to be addressed.
We compared the list of the 1266 genes for which we
found HPV(+)-associated DMPs with other DNA
methylation changes of HPV(+) HNSCC, obtained with
different genome-wide platforms (Illumina Golden Gate
or Illumina HumanMethylation27 bead-array, MCIp-
Agilent 244 K). While a formal comparison with the
published signatures was not possible due to the lack of
overlap at single CpG sites across the platforms, we com-
prehensively included all the genes mentioned in each
paper (Additional file 3). This comparison revealed that
our HPV(+) signature included many of the hypermethy-
lated genes previously described [2, 3, 5, 7–9] (Additional
file 3). Our analysis also identified hypermethylation of
new genes associated with HPV status, including two other
cadherin-associated genes (CDH18 and CTNND2) for
which methylation levels were not previously described as
deregulated in HPV(+) tumours. A systematic ad hoc
search for biological functions indicated that hypermethy-
lated genes shared by all anatomic sites are mainly involved
in neuronal differentiation, calcium signalling and encod-
ing of DNA-binding zinc finger proteins, the latter previ-
ously observed in another study [3] (Additional file 3).
Interestingly, our analysis also revealed that 60% of dif-
ferentially methylated genes (756 out of 1266) associated
with HPV(+) HNSCCs were hypomethylated. The main
biological functions associated to the hypomethylated
genes common to all anatomic sites were apoptosis, cell
cycle regulation and non-coding RNAs (ncRNAs), of
which two have been described as deregulated in
leukemias (DLEU1 and mir9-3) (Additional file 3).
Hypomethylated regions in CpG shores are associated
with HPV infection and activated gene expression
Since alterations in DNA methylation can affect multiple
neighbouring CpG sites, we applied dimension reduction
to identify differentially methylated regions (DMRs, at
least three CpGs in a 1-kb region), using the DMRcate
package (see Methods for details) in the whole dataset
(Additional files 4 and 5) and in each stratified organ
group (Additional files 6, 7 and 8). Globally, we identified
4371 hypermethylated DMRs and 2044 hypomethylated
DMRs (FDR <0.05). However, using more stringent criteria
(increasing the differential methylation to Δβmax >20% or
Δβmax >30%), we found an increased proportion (from 32%
to 65% or 95%, respectively) of hypomethylated regions
associated with HPV(+) status (Table 2). Interestingly, we
found that average methylation levels of the top 25 hypo-
methylated and top 25 hypermethylated DMRs (Additional
files 4, 5, 6, 7 and 8) were able to separately cluster HPV(+)
from HPV(–) HNSCCs for each anatomic site (57/63)
(Fig. 3a, Additional file 2: Figure S2D–F). Globally, both
hyper- and hypomethylated regions presented an
enrichment not only in CpG islands, as previously de-
scribed, but also in shores (Fig. 3b), thus revealing new
genomic regions targeted by DNA methylation changes in
HPV(+) HNSCCs.
In order to investigate potential functional effects of
DNA hypomethylation in these regions, we first plotted
gene expression log2 fold changes (log2FC) and DNA
methylation changes (Δβmax >20%) of the genes belong-
ing to the DMRs found with a Δβmax >20%. Gene
expression data were available for 165 genes (105 hypo-
methylated and 60 hypermethylated) for the TCGA
cohort and were extracted from the cBioPortal. We
found that 49 out of 105 genes located in hypo-DMRs
showed an increased gene expression (log2FC >2), while
15 out of 60 genes located in hyper-DMRs showed de-
creased gene expression (log2FC <2) (p value < 0.006, χ
2
test) (Fig. 4). We then systematically analysed the 50 most
differentially methylated regions (Stouffer FDR <0.05;
ranked by Δβmax). Similarly, we found a significant
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Fig. 2 HPV infection leaves clear DNA methylation signature in HNSCCs. MDS plots showing sample clustering grouped by different variables: a HPV
status, b organ site, c smoking status, d alcohol consumption. e Heatmap showing the 2410 DMPs associated with HPV status (FDR <0.05, Δβ >20%)
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correlation (Pearson, p value < 0.05) between average
DNA methylation levels and gene expression in 52%
(13 out of 25 cases) of the genes located in hypo-
DMRs and in 4% (1 out of 25 cases, ZNF733) of the
genes located in hyper-DMRs (p value < 0.001, χ2 test)
(TCGA dataset) (Additional file 9).
As in previous studies, we observed an inverse correl-
ation between DNA methylation and gene expression
(Fig. 3c, Fig. 4, Additional file 9). Unexpectedly, these re-
sults suggest that hypermethylated DMRs are less likely
to affect gene expression than hypomethylated DMRs in
this context (Additional file 9). The number of analysed
genes whose expression was affected by DNA methyla-
tion changes in the DMRs was too low to get meaningful
results from pathway analyses. However, we found
three hypomethylated genes which were overexpressed
Table 2 Number of differentially methylated regions (DMRs)
identified by DMRcate (minimum three CpGs in a 1-kb window)
based on the maximum differential methylation in the region
Δβ threshold Hypomethylated DMRs Hypermethylated DMRs
No threshold 2044 (32%) 4372 (78%)
Δβmax >5% 1716 (32%) 3788 (78%)
Δβmax >10% 797 (33%) 1592 (67%)
Δβmax >20% 112 (65%) 61 (35%)
Δβmax >30% 20 (95%) 1 (5%)
Fig. 3 Hypomethylated DMRs associated with HPV infection show CpG island shore loss of boundary and functional correlation with gene expression.
a Heatmap showing the top 50 DMRs associated with HPV status (FDR <0.05). b CpG context of the identified DMRs in the different anatomic sites
compared with their distribution in the Illumina HumanMethylation 450 K array (HM450). c Correlation between CpG methylation at the SYCP2 DMR
and relative gene expression in the HNSCC cases of the TCGA cohort. HPV(+) cases are indicated by full pink dots, HPV(–) cases by empty blue dots.
d Co-methylation plots showing the CpGs in SYCP2 DMR ranked by p value and visualized based on their chromosomal coordinates, relative position
to CpG island (green bar) and CpG content (red peak). The average methylation values in the DMR in HPV(+) (pink) or HPV(–) (blue) cases are shown.
The correlation plot shows Spearman correlation values among the CpGs in the region
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in HPV(+) HNSCCs, all of which are involved in the
extracellular matrix organization (NCAN, NRXN1,
COL19A1). Other hypomethylated genes whose ex-
pression was increased in HPV(+) cases were involved
in structural maintenance of chromosomes during
mitosis/meiosis (SYCP2, RPA2, SMC1B). The package
CoMet plot [19] was next used to visualize regional
epigenome-wide co-methylation associations and to
expand the analysis to a 10-kb region around each
DMR. We found that methylation patterns at the sin-
gle CpG level were significantly and positively
correlated when located in close proximity to the
DMRs (Fig. 3d, Additional file 9). Moreover, most
DMRs which showed a correlation with gene expres-
sion presented a marked loss of CpG island boundar-
ies (Fig. 3d, Additional file 9), a feature previously
described in other cancer types and associated with
cancer development [23, 24]. A similar trend was ob-
served for genes besides the top 25 DMRs systematically
analysed (such as MEIS1, STAT5A), suggesting that
the functional impact of DNA hypomethylation in the
CpG shores on gene expression may be generalized
(Additional file 9).
Interestingly, our search for transcription factor binding
sites (TFBSs) across DMRs showed an enrichment of
TFBS motifs related to c-MYC in hypomethylated DMRs.
Actually, c-MYC is typically amplified in HPV16 cervical
squamous cell carcinomas [25, 26], and its binding to the
consensus DNA element is reported to be methylation-
sensitive, in particular at CpG islands and nearby regions,
supporting our finding of an interaction at hypomethy-
lated regions at CpG island shores [27, 28].
HPV(+) HNSSCs showed an organ-site-independent DNA
methylation signature of clinical relevance
To test whether HPV-associated methylation changes may
be predictive of HPV status, we next analysed the normal-
ized data using a prediction analysis of microarrays (PAM)
algorithm and a random forest (RF) algorithm (see
Methods section), performing five cross-validations for
each method. ROC curve (AUC) analysis showed that
methylation values of as low as 10 CpGs (Fig. 5a, b) were
able to give AUC >0.95 in most of the training and the test
sets (Fig. 5c, d). Predictive signatures of 10 CpGs for each
cross-validation resulted in an average sensitivity of 89%
(87–94%) and an average specificity of 96% (95–97%) in
the training test. In the test set, the average sensitivity was
89% (83–94%) and the average specificity was 95% (range
94–97%). The recurrent CpGs across the five cross-
validated signatures of 10 CpGs were localized in the
B3GALT6-SDF4 locus (3 CpGs), in the SYCP2-FAM217B
locus (1 CpG), the HLTF-HLTF-AS1 locus (from 1 to
3 CpGs), TLX2 gene (from 1 to 2 CpGs), LOC729683
(from 1 to 2 CpGs), IL4I4 gene (1 CpG) and
LINC00925 (1 CpG).
To validate the predicted signatures using alternative
quantitative methods, such as pyrosequencing, we
selected the five most recurrent CpGs appearing in the
10-CpG signatures of each cross-validation. In particular,
we used the three CpGs localized in the B3GALT6-SDF4
locus (cg13924635, cg22220310, cg14477263), in the
SYCP2-FAM217B locus (cg21950459) and in the HLTF-
HLTF-AS1 locus. We used the average methylation
levels of these five CpGs to create an average methyla-
tion index (AMI), and we set a β-value cut-off of 0.75
(corresponding to 75% of methylation in the pyrose-
quencing results) (see Methods). By applying this ap-
proach to the entire French cohort (38 cases, 9 HPV(+)),
we obtained a sensitivity of 66.7% and a specificity of
93.1%, further verifying the robustness and predictive
power of our HPV-specific methylation signature
(Fig. 5e). Finally, we used our 5-CpG signature to stratify
303 cervical squamous cell carcinomas from TCGA and
found that 66% of them showed similar levels of methy-
lation compared with HPV(+) HNSCCs (Fig. 5f ).
Finally, we tested whether our 5-CpG signature was a
good predictor of survival, since HPV(+) status is associ-
ated with better survival than HPV(–) status in HNSCCs.
Indeed, when HPV status determined with viral gene ex-
pression was used to stratify the patients, patients with
HPV(+) showed better survival than patients with HPV(–)
after almost 8 years of follow-up (2898 days) (52% vs 27%,
Fig. 4 DNA methylation changes associated with gene expression
changes in the TCGA cohort. Starburst plot showing correlations
between gene expression changes and DNA methylation changes in
DMRs with Δβ >20%. Red dots indicate up-regulated genes in
HPV(+) cases with a minimum logFC >1. Purple dots indicate
down-regulated genes with a minimum logFC < –1. Grey dots
indicate genes with expression changes –1 < logFC < 1 and changes
in methylation with Δβ >20%
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p value = 0.003, χ2 test) (Fig. 6a). Interestingly, for the
same follow-up period, we found that patients with a low
AMI showed a 62% survival rate, while patients with a
high AMI showed a 25% survival rate (p value = 0.0003, χ2
test) (Fig. 6b). These results indicate that our HPV-
associated epigenetic signature may be used as a predictor
of survival for HPV(+) HNSSCs.
Discussion
In this study we present the first pooled analysis of
genome-wide DNA methylation data from HM450K in
HNSCCs. Compared with the largest cohort (TCGA) for
which HM450K data were available, the pooled cohorts
have 43% more HPV(+) cases analysed (63 vs 36), lead-
ing to a prevalence of 19% of HPV(+) cases. Moreover,
Fig. 5 DNA methylation predictive signature of HPV status in HNSCCs. a Overall and class-specific misclassification errors based on the number of
CpGs selected to predict HPV status. b AUC values from PAM algorithm according to the number of probes selected to predict the HPV status.
The red dot indicates the AUC for 10-CpG signatures. Similar results were obtained using RF algorithm (data not shown). c Receiver operating
characteristic (ROC) curves (AUC) using the training set data. d ROC curves (AUC) using the test set data. e Average methylation index (AMI) of
the 5-CpG signature across the different datasets (TCGA cohort, UCL cohort, FITMANET cohort 450 K, FITMANET validation cohort). f AMI of the
5-CpG signature in cervical carcinomas from TCGA. Similar to HNSCCs signature, high methylation is considered when the AMI is higher than 0.75
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many head and neck organs are included, allowing an
assessment of HPV methylation signatures in different
anatomic sites. Globally, our results show that HPV has
a specific and genome-wide effect in shaping the DNA
methylome of HNSCCs that is independent of other
known major risk factors, such as tobacco smoking and
alcohol consumption. Our results are similar to a recent
report based on the analysis of the whole TCGA cohort
[29]. The authors identified five subclusters of HNSSC
based on DNA methylation patterns (528 samples), four
HPV(–) clusters and one HPV(+) cluster [29].
Previous works reported aberrant hypermethylation in
gene promoters of HPV(+) oropharyngeal cancer cases
[2, 3, 9]. Identified target genes differed between the
studies: Lleras et al. [3] reported CDKN2A and GALR1
among the most hypermethylated gene promoters;
Lechner et al. [2] reported Polycomb repressive complex
2 target genes, mainly cadherin coding genes; while
Kostareli et al. [9] reported ALDH1A2, OSR2, GATA4,
GRIA4 and IRX4 as the most hypermethylated gene
promoters. Differences in the various studies may be
attributed to the different platforms used (Illumina
Methylation 27 K, HM450K, Agilent 244 K), different
tissue conservation (frozen or FFPE) and relatively small
sample sizes. However, we found a marked overlap with
the genes described by Lechner et al. [2], whose dataset
was included in our pooled analysis. Moreover, while the
different published signatures showed no overlap among
the hypermethylated genes, our signature showed partial
overlap to each of them (although we cannot exclude
that we missed partial overlaps among the published
signatures due to partial reporting in the papers). In
addition, our analysis identified hypermethylation of new
genes associated with HPV status, including two add-
itional cadherin-associated genes (CDH18 and CTNND2)
for which methylation levels were not previously described
as deregulated in HPV(+) tumours. Interestingly, among
the hypermethylated DMRs we systematically analysed in
order to look at their potential impact on gene expression,
we found a zinc finger factor coding gene (ZNF733), a
gene family for which promoter hypermethylation and
consequent down-regulated expression were previously
described in HNSCCs [3].
To date, only few hypomethylated genes have been
linked to HPV status [2, 5, 7–9]. Our analyses found
60% of differentially methylated genes were hypomethy-
lated. These results highlight the power of our pooled
analysis in identifying novel genes and regions in which
methylation levels are influenced by HPV infection. Im-
portantly, we found that hypomethylated DMRs were
more likely to affect gene expression than hypermethylated
DMRs. This result extends to HNSCC previous observa-
tions on hypomethylated blocks in some human solid tu-
mours [23, 24]. Our motif enrichment analysis suggests
that c-MYC-induced immortalization may be facilitated by
the hypomethylation of many of its potential target genes.
Among the most hypomethylated regions we found to be
associated with increased gene expression was that in the
CpG island shore of the SYCP2 gene (Fig. 3). In fact, a
recent study describes that SYCP2 up-regulation predicts
early stage HPV(16) oropharyngeal carcinomas [28].
Moreover, we identified a minimal epigenetic signature
made of five CpGs encompassing three genetic loci
(B3GALT6-SDF4, SYCP2-FAM127B and HTLF-HLTF-
AS1) that showed a high specificity (>95%) in identifying
HPV(+) cases, independent of the anatomic site. Indeed,
one of the CpGs belonging to our 5-CpG predictive signa-
ture of HPV status belongs to the SYCP2 DMR, suggesting
that its up-regulation is functionally mediated by HPV-
Fig. 6 DNA methylation signature predictive of survival in the TCGA
cohort. a Kaplan-Meier survival curve based on HPV status determined
by viral gene expression using RNA-sequencing data. b Kaplan-Meier
survival curve based on the average methylation index (AMI) of the
5-CpG signature. LowAMI corresponds to an AMI less than 0.75, while
highAMI corresponds to an AMI higher than 0.75
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associated demethylation at its close CpG island shore.
Finally, our signature seems to have potentially important
clinical relevance. Notably, we showed that this epigenetic
signature was a better predictor of survival compared with
HPV status itself (assessed with the highly accurate
method of measuring viral gene expression using RNA-
sequencing data) in the TCGA cohort (Fig. 6). While
further studies are needed to investigate the precise
molecular mechanism underlying these findings, one can
speculate that this epigenetic signature is able to integrate
the different epigenetic alterations induced by the multiple
exposures occurred in these patients (notably, heavy smok-
ing, alcohol consumption and HPV infection), resulting in
a better discriminator for survival.
Conclusions
Our results based on genome-wide DNA methylation
data from different cohorts show that HPV infection
greatly affects DNA methylation in HNSCCs across
different anatomic sites. Our analyses are based on a
pooled large dataset, and our results expand and com-
plement those already published [30]. As previously de-
scribed, we observed a higher prevalence of HPV(+)
cases in men than in women [31]. A limitation of the
analysis regards the lack of complete smoking/alcohol
data, as this has limited our ability to assess differences
based on smoking. We determined that previously ob-
served hypermethylation in some promoter-associated
CpG islands is less likely to correlate with gene expres-
sion than the hypomethylated CpG island shores we
identified, which showed a strongly significant correl-
ation with the expression of associated genes. As few as
five of these methylation changes provided a highly spe-
cific predictive signature of HPV status, suggesting that
HPV drives some DNA methylation-dependent molecu-
lar events, for example, higher nucleosome accessibility
to c-Myc transcription factor [32]. Intriguingly, the sen-
sitivity we observed in the validation cohort and the
fraction of cervical cancer showing a lowly methylated
score (66.7%, 66%, respectively) reflects the HPV16
prevalence in cervical cancer (around 70%) [33], suggest-
ing potential HPV subtype-specific methylation changes,
since HPV16 was the most common subtype (89%
prevalence) in the HNSCCs analysed in this study. While
we do not estimate that our epigenetic signature might
replace current diagnostic methods in a short time
frame, our signature is a promising predictor of survival
for HNSCCs. However, our signature should be tested in
larger cohorts of patients with HNSCC, using multivari-
ate statistical models, to improve the power and eventu-
ally provide a better marker for establishing more
targeted treatments, especially when considering HPV
status for de-escalation regimens to avoid long-term tox-
icity of standard-of-care treatment.
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